WASHINGTON (dpa-AFX) - Novo Nordisk A/S (NVO) announced the top-line results
from the sixth and last global phase 3a trial, SUSTAIN6, for semaglutide; a new
GLP-1 analogue, which is administered subcutaneously once weekly in the SUSTAIN
Novo Nordisk didn't know how fraught its path would be with Tresiba in 2012, when it won Japanese approval for the drug. The company continued to build up Tresiba in the country even as it struggled to gain stateside approval for the med. But...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):